DE2620483A1 - Stabile waessrige insulinloesungen - Google Patents
Stabile waessrige insulinloesungenInfo
- Publication number
- DE2620483A1 DE2620483A1 DE19762620483 DE2620483A DE2620483A1 DE 2620483 A1 DE2620483 A1 DE 2620483A1 DE 19762620483 DE19762620483 DE 19762620483 DE 2620483 A DE2620483 A DE 2620483A DE 2620483 A1 DE2620483 A1 DE 2620483A1
- Authority
- DE
- Germany
- Prior art keywords
- insulin
- aqueous
- solution according
- stable
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 176
- 102000004877 Insulin Human genes 0.000 title claims description 87
- 108090001061 Insulin Proteins 0.000 title claims description 87
- 229940125396 insulin Drugs 0.000 title claims description 87
- 239000000243 solution Substances 0.000 claims description 37
- -1 polyoxyethylene Polymers 0.000 claims description 18
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000004359 castor oil Substances 0.000 claims description 6
- 235000019438 castor oil Nutrition 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- 210000002850 nasal mucosa Anatomy 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 2
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 239000002736 nonionic surfactant Substances 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 101001011741 Bos taurus Insulin Proteins 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 206010040576 Shock hypoglycaemic Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 108010092217 Long-Acting Insulin Proteins 0.000 description 1
- 102000016261 Long-Acting Insulin Human genes 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101000993800 Sus scrofa Insulin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000002633 shock therapy Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2535175A GB1554157A (en) | 1975-06-13 | 1975-06-13 | Stable insulin preparation for intra nasal administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2620483A1 true DE2620483A1 (de) | 1976-12-23 |
Family
ID=10226264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19762620483 Withdrawn DE2620483A1 (de) | 1975-06-13 | 1976-05-08 | Stabile waessrige insulinloesungen |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS51148013A (enrdf_load_stackoverflow) |
| BE (1) | BE841870A (enrdf_load_stackoverflow) |
| DE (1) | DE2620483A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2313914A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1554157A (enrdf_load_stackoverflow) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2917535A1 (de) * | 1979-04-30 | 1980-11-06 | Hoechst Ag | Gegen denaturierung bestaendige insulinloesungen, ihre herstellung und verwendung |
| EP0018609A1 (de) * | 1979-04-30 | 1980-11-12 | Hoechst Aktiengesellschaft | Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung |
| WO1983000288A1 (en) * | 1981-07-17 | 1983-02-03 | Balschmidt, Per | A stable aqueous, therapeutic insulin preparation and a process for preparing it |
| DE3443877A1 (de) * | 1984-06-09 | 1985-12-12 | Hoechst Ag | Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| US6932962B1 (en) | 1994-12-22 | 2005-08-23 | Astrazeneca Ab | Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783441A (en) * | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| JPS61267528A (ja) * | 1984-11-26 | 1986-11-27 | Yamanouchi Pharmaceut Co Ltd | 吸収促進剤を含有するカルシトニン経鼻剤 |
| CA1274774A (en) * | 1985-04-15 | 1990-10-02 | Kenneth S. Su | Method for administering insulin |
| DK179286D0 (da) * | 1986-04-18 | 1986-04-18 | Nordisk Gentofte | Insulinpraeparat |
| CA1291036C (en) * | 1986-04-23 | 1991-10-22 | Edwin I. Stoltz | Nasal administration of drugs |
| ES2045276T3 (es) * | 1988-07-21 | 1994-01-16 | Hoffmann La Roche | Preparacion de insulina |
| ATE164080T1 (de) * | 1990-05-10 | 1998-04-15 | Bechgaard Int Res | Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| DE602004028284D1 (de) * | 2003-12-08 | 2010-09-02 | Cpex Pharmaceuticals Inc | Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung |
| US7851419B2 (en) * | 2005-09-12 | 2010-12-14 | Nawaz Ahmad | Substantially anhydrous sprayable personal lubricant |
| AU2009305472B2 (en) | 2008-10-17 | 2013-12-19 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1 agonist |
| RU2537239C2 (ru) | 2009-11-13 | 2014-12-27 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин |
| KR101772372B1 (ko) | 2009-11-13 | 2017-08-29 | 사노피-아벤티스 도이칠란트 게엠베하 | Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물 |
| BR112013004756B1 (pt) | 2010-08-30 | 2020-04-28 | Sanofi Aventis Deutschland | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| ITRM20110390A1 (it) | 2011-07-21 | 2013-01-22 | Eramo Alessandra D | Prodotto per stimolare la produzione endogena di mediatori dell'infiammazione. |
| SI2750699T1 (sl) | 2011-08-29 | 2015-11-30 | Sanofi-Aventis Deutschland Gmbh | Farmacevtska kombinacija, za uporabo pri glikemični kontroli pri pacientih, ki imajo sladkorno bolezen tipa 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| EP3030294B1 (en) * | 2013-08-05 | 2020-10-07 | MannKind Corporation | Insufflation apparatus |
| BR112017012406A2 (pt) | 2014-12-12 | 2018-07-31 | Sanofi Aventis Deutschland | formulação com relação fixa de insulina glargina/lixisenatida |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL62232C (enrdf_load_stackoverflow) * | 1900-01-01 | |||
| US3096249A (en) * | 1960-05-10 | 1963-07-02 | Samuel J Prigal | Emulsion composition |
-
1975
- 1975-06-13 GB GB2535175A patent/GB1554157A/en not_active Expired
-
1976
- 1976-05-08 DE DE19762620483 patent/DE2620483A1/de not_active Withdrawn
- 1976-05-13 JP JP5493176A patent/JPS51148013A/ja active Pending
- 1976-05-14 FR FR7614706A patent/FR2313914A1/fr active Granted
- 1976-05-14 BE BE167069A patent/BE841870A/xx not_active IP Right Cessation
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2917535A1 (de) * | 1979-04-30 | 1980-11-06 | Hoechst Ag | Gegen denaturierung bestaendige insulinloesungen, ihre herstellung und verwendung |
| EP0018609A1 (de) * | 1979-04-30 | 1980-11-12 | Hoechst Aktiengesellschaft | Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung |
| WO1983000288A1 (en) * | 1981-07-17 | 1983-02-03 | Balschmidt, Per | A stable aqueous, therapeutic insulin preparation and a process for preparing it |
| DE3443877A1 (de) * | 1984-06-09 | 1985-12-12 | Hoechst Ag | Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| US6932962B1 (en) | 1994-12-22 | 2005-08-23 | Astrazeneca Ab | Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2313914B1 (enrdf_load_stackoverflow) | 1979-04-13 |
| JPS51148013A (en) | 1976-12-18 |
| FR2313914A1 (fr) | 1977-01-07 |
| GB1554157A (en) | 1979-10-17 |
| BE841870A (fr) | 1976-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2620483A1 (de) | Stabile waessrige insulinloesungen | |
| DE69104724T2 (de) | Florfenicol enthaltendes arzneimittel. | |
| EP0242328B1 (de) | Arzneimittel zur Behandlung von Entzündungen im Auge | |
| DE60011589T2 (de) | Hochwirksame dihydroergotaminhaltige arzneizusammensetzungen | |
| DE69328192T4 (de) | Injizierbare Arzneizubereitungen enthaltend Taxanderivate | |
| DE3751761T2 (de) | Penetrationsverbesserer für die transdermale Verabreichung von systemisch wirksamen Arzneimitteln | |
| DE2620446A1 (de) | Waessriges insulinpraeparat | |
| DE1670827B2 (de) | 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-di carbmethoxy-1,4-dihydropyridin | |
| DE69027220T2 (de) | Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen | |
| WO1985002342A1 (en) | Drug with improved penetration into the tissular membrane | |
| DE4139017C2 (de) | Wäßrige Piroxicam-Lösungen und Verfahren zu ihrer Herstellung | |
| EP0357978A1 (de) | Pharmazeutische Zubereitung zur Behandlung des Diabetes mellitus | |
| EP0185210A2 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| CH650678A5 (de) | Pharmazeutisches mittel aus human-insulin und human-proinsulin. | |
| EP0277462B1 (de) | Verfahren zur Herstellung nasaler Lösungen enthaltend synthetisches Human calcitonin. | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
| DE2743586C2 (de) | Injizierbare Lösung, die L-Pyroglutamyl-L-histidyl-L-prolinamid oder ein physiologisch unbedenkliches Salz hiervon enthält | |
| EP0267404B1 (de) | Dermale Behandlung von Wurmerkrankungen der Katze mit Praziquantel | |
| EP0493662B1 (de) | Verwendung von Superoxiddismutasen für die Herstellung von Arzneimitteln zur Prophylaxe und/oder Behandlung von Organversagen bei Risikopatienten mit Polytrauma als Unfallfolge | |
| DE60101979T2 (de) | Lösung enthaltend N-[O-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glyzin Mononatriumsalz Tetrahydrat und diese Lösung enthaltendes Arzneimittel | |
| DE1668171A1 (de) | Verfahren zur herstellung von stabilen waessrigen loesungen neuer komplexer organosiliciumverbindungen | |
| DE2829408A1 (de) | Bestaendige injizierbare chloramphenicolzusammensetzung | |
| DE69922252T2 (de) | Parenterale lösungen enthaltend propofol (2,6-diisopropylphenol) und 2.5-di-0-methyl-1.4;3.6-dianhydro-d-glucitol als lösungsmittel | |
| DE2518509C3 (de) | Pharmazeutisches Mittel für Antitumoraktivität, enthaltend Abrin | |
| DE2314387C3 (de) | Arzneimittel zur Behandlung bösartiger Neubildungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8141 | Disposal/no request for examination |